Company | Date | Price Target | Rating | Analyst |
---|---|---|---|---|
9/10/2024 | $295.00 | Buy | Deutsche Bank | |
9/6/2024 | $206.00 → $169.00 | Underweight → Equal Weight | Barclays | |
9/5/2024 | Peer Perform | Wolfe Research | ||
8/29/2024 | Outperform | William Blair | ||
7/24/2024 | $162.00 → $215.00 | Hold | Truist | |
7/24/2024 | $274.00 → $258.00 | Neutral | Citigroup | |
7/24/2024 | $248.00 → $230.00 | Neutral | Goldman | |
7/24/2024 | $205.00 → $300.00 | Overweight | Piper Sandler |
ZURICH, Sept. 4, 2024 /PRNewswire/ -- Amcor (NYSE:AMCR, ASX: AMC))), a global leader in developing and producing responsible packaging solutions, today announced that its Board of Directors has appointed Peter Konieczny as Chief Executive Officer (CEO). Mr. Konieczny has served as Interim CEO since April 2024. The Board also intends to nominate him as a director for election at the Company's Annual Meeting of Shareholders which is expected to be held in November 2024. Amcor Chairman, Mr. Graeme Liebelt, said, "Peter has demonstrated exceptional leadership in every role he has
Aditxt, Inc. ("Aditxt" or the "Company") (NASDAQ:ADTX), an innovation platform dedicated to discovering, developing, and deploying promising health innovations, today announced that its subsidiary, Pearsanta, Inc. ("Pearsanta"), appointed Christoper Mitton as President. Christopher Mitton brings over 20 years of leadership experience in the medical diagnostics industry, with a strong focus on personalized healthcare and molecular oncology diagnostics. He has a proven track record in building and leading successful commercial operations, underpinned by his deep expertise in product commercialization, business development, and strategic sales and marketing. Mr. Mitton continues to serve as
Tesla Is Now a Texas Corporation At today's Annual Stockholders' Meeting, Tesla stockholders overwhelmingly approved the ratification of the 2018 CEO Performance Award and the redomestication of the Company to Texas. Tesla has submitted all filings to effectuate its conversion into a Texas corporation and can confirm that the Company is now incorporated in Texas. Full voting results for its 2024 Annual Meeting of Stockholders are below. AGENDA ITEM PROPOSAL BOARD VOTE RECOMMENDATIONS VOTING RESULTS Tesla Proposals 1. A Tesla proposal to elect two Class II directors, James Murdoch and Kimbal Musk, to serve for a term of three years, or until th
144 - Coinbase Global, Inc. (0001679788) (Subject)
144 - Coinbase Global, Inc. (0001679788) (Subject)
8-K - AMC ENTERTAINMENT HOLDINGS, INC. (0001411579) (Filer)
Deutsche Bank resumed coverage of Tesla with a rating of Buy and set a new price target of $295.00
Barclays upgraded Coinbase Global from Underweight to Equal Weight and set a new price target of $169.00 from $206.00 previously
Wolfe Research resumed coverage of Tesla with a rating of Peer Perform
Adjusted EBITDA Increased to $6.4 Million for the First Half of 2024 Conference Call and Webcast on September 16th at 8 AM ET NEW YORK, Sept. 16, 2024 /PRNewswire/ -- SunCar Technology Group Inc. (the "Company" or "SunCar") (NASDAQ:SDA), an innovative leader in cloud-based B2B software-focused auto services and auto e-insurance in China, today provided a business update and reported financial results for the first half of fiscal year 2024. First Half 2024 Financial Results Total revenue increased by 27% to $203.1 million for the six months ended June 30, 2024, from $159.4 million for the six months ended June 30, 2023.Auto Services ' revenue increased by 9% to $107.5 million for the six mo
— Improved loss from operations by 81% — — Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health infections — — Forged ex-U.S. commercial agreement for Phexxi in Middle East — SAN DIEGO, Aug. 14, 2024 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. ("Evofem" or "the Company") (OTCQB:EVFM) today announced financial results for the second quarter and first half of 2024. Highlights include: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Women's health innovator Evofem Biosciences (OTCQB:EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)">
Ozuriftamab vedotin (CAB-ROR2-ADC) granted Fast Track Designation by FDA in squamous cell carcinoma of the head and neck (SCCHN); anticipate FDA meeting for SCCHN potential registrational trial in 2H 2024Evalstotug (CAB-CTLA-4 antibody) demonstrated a similar low incidence and severity of immune-related adverse events across both Phase 1 and 2 studies; Phase 2 combination with pembrolizumab study continues to enroll and on track for initial data readout in 2H 2024Mecbotamab vedotin (CAB-AXL-ADC) Phase 2 trial in NSCLC showed trend for improved overall survival among treated patients with tumors expressing mutated KRAS variants compared to KRAS wildtype; anti-tumor activity across multiple KR
4 - BioAtla, Inc. (0001826892) (Issuer)
4 - BioAtla, Inc. (0001826892) (Issuer)
4 - BioAtla, Inc. (0001826892) (Issuer)
4 - Coinbase Global, Inc. (0001679788) (Issuer)
4 - Coinbase Global, Inc. (0001679788) (Issuer)
4 - Coinbase Global, Inc. (0001679788) (Issuer)
An ongoing complete response (CR) with an overall response rate (ORR) of 32% achieved across two dosing regimens Underscores ozuriftamab vedotin's activity in a high unmet need SCCHN patient population The conditionally binding ADC targeting ROR2 was notably well tolerated The Company intends to meet with the FDA to discuss a SCCHN potential registrational trial in 2H 2024 SAN DIEGO, Sept. 16, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today presented a poster of promising Phase 2 trial data at the European
Adjusted EBITDA Increased to $6.4 Million for the First Half of 2024 Conference Call and Webcast on September 16th at 8 AM ET NEW YORK, Sept. 16, 2024 /PRNewswire/ -- SunCar Technology Group Inc. (the "Company" or "SunCar") (NASDAQ:SDA), an innovative leader in cloud-based B2B software-focused auto services and auto e-insurance in China, today provided a business update and reported financial results for the first half of fiscal year 2024. First Half 2024 Financial Results Total revenue increased by 27% to $203.1 million for the six months ended June 30, 2024, from $159.4 million for the six months ended June 30, 2023.Auto Services ' revenue increased by 9% to $107.5 million for the six mo
Marcus Glover will serve as a Class 1 director of the Company with a term expiring at the Company's 2027 Annual Meeting of Stockholders AMC Entertainment Holdings, Inc., (NYSE:AMC), the largest theatrical exhibitor in the United States and in the world, today announced that the Company's Board of Directors has elected Marcus Glover to the AMC Board of Directors, effective September 12, 2024. Glover will serve as a Class 1 director of the Company with a term expiring at the Company's 2027 Annual Meeting of Stockholders, and at that meeting will stand for re-election thereafter. He will serve as a Member of the Audit Committee. Glover brings to the Board extensive financial, operational an
SC 13D/A - BioAtla, Inc. (0001826892) (Subject)
SC 13G - BioAtla, Inc. (0001826892) (Subject)
SC 13G - AMC ENTERTAINMENT HOLDINGS, INC. (0001411579) (Subject)
To gain an edge, this is what you need to know today. GDP Brings Buying Please click here for an enlarged chart of Invesco QQQ Trust Series 1 (NASDAQ:QQQ). Note the following: The chart shows a drop in QQQ. The drop in QQQ was triggered by speculative sentiment pulling back. As a reader of The Arora Report, you knew in advance that speculative sentiment could fall as a result of Tesla Inc (NASDAQ:TSLA) earnings. The chart shows that QQQ is approaching the support zone. RSI on the chart shows that QQQ is now oversold. Oversold markets tend to bounce. The chart shows that the volume was low on the selloff. This indicates a lack of conviction in selling. Especially hard hit in
Honda Motor Co. (NYSE:HMC) will reduce its production of gasoline vehicles in China by 19% starting this October, marking a strategic shift toward electric vehicles. The Japanese automaker will cease operations of one production line at its joint venture Dongfeng Honda, which has an annual capacity of 240,000 units, beginning in November. Additionally, in October, GAC Honda, another of its facilities with a capacity of 50,000 units annually, will be completely shut down. These changes are part of Honda's effort to accelerate the “steady shift” to EVs, reported Bloomberg. Honda’s production capacity in China, currently around 1.5 million units, will see a reduction of 19% due to
https://x.com/elonmusk/status/1816478001884004816https://x.com/elonmusk/status/1815907844434112999